

Mini review

CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling



Nicla Porciello, Loretta Tuosto*

Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy

ARTICLE INFO

Article history:

Received 1 February 2016

Accepted 22 February 2016

Available online 4 March 2016

Keywords:

T cells

CD28

NF-κB

Cytokines

Inflammation

ABSTRACT

CD28 is one of the most important co-stimulatory receptors necessary for full T lymphocyte activation. By binding its cognate ligands, B7.1/CD80 or B7.2/CD86, expressed on the surface of professional antigen presenting cells (APC), CD28 initiates several signalling cascades, which qualitatively and quantitatively support T cell receptor (TCR) signalling. More recent data evidenced that human CD28 can also act as a TCR-independent signalling unit, by delivering specific signals, which regulate the expression of pro-inflammatory cytokine/chemokines. Despite the enormous progresses made in identifying the mechanisms and molecules involved in CD28 signalling properties, much remains to be elucidated, especially in the light of the functional differences observed between human and mouse CD28. In this review we provide an overview of the current mechanisms and molecules through which CD28 support TCR signalling and highlight recent findings on the specific signalling motifs that regulate the unique pro-inflammatory activity of human CD28.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Optimal T cell response to antigen is achieved following the recognition of peptide-major histocompatibility complex (MHC) by TCR (signal one) together with a subset of co-stimuli (signal

two), generally provided by counter-receptors expressed on the surface of APCs. Since its discovery in early 1980s, CD28 has been considered the most prominent co-stimulatory molecule for optimal T cell clonal expansion, differentiation and effector functions. CD28 is a 44 kDa glycosylated, disulfide-linked homodimeric type I transmembrane protein expressed on the surface of 80% of human CD4⁺ T cells, 50% of human CD8⁺ T cells [1] and 100% of both murine CD4⁺ and CD8⁺ T cells [2]. CD28 binds to B7.1/CD80 and/or B7.2/CD86, expressed on the surface of activated APCs (i.e. macrophages, dendritic cells, B lymphocytes), through a MYPPPY motif within its extracellular immunoglobulin (Ig)-V-like domain [3,4] and to B7-H2 through a region outside the MYPPPY motif [5].

The most discernable effects of CD28 ligation have been observed in concert with TCR stimulation. By delivering signals that complement TCR, in both qualitative and quantitative manners [6,7], CD28 promotes/enhances entry into and progression through the cell cycle, high levels of cytokines, cell survival and T cell differentiation [8]. More evidences have recently shown that CD28 may also deliver unique signals independent of TCR [9–13]. All the signalling properties of CD28 rely on specific and distinct motifs within its short cytoplasmic tails that initiate specific protein-protein interactions, thus activating downstream signalling cascades essential for CD28 costimulatory functions.

Abbreviations: MHC, major histocompatibility complex; TCR, T-cell receptor; APC, antigen presenting cell; Ig, immunoglobulin; IL, interleukin; IS, immunological synapse; PLCγ1, phospholipase Cγ1; LAT, linker for activation of T cells; Grb2, growth-factor receptor-bound protein; GADS, Grb2-related adaptor downstream of Shc; PKCθ, protein kinase C θ; ERK, extracellular signal regulated kinases; JNK, jun N-terminal kinases; NF-AT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; AP-1, activator protein 1; UTR, 3'untranslated region; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3 kinase; Nck, noncatalytic region of tyrosine kinase; WASp, Wiskott Aldrich syndrome protein; Arp, actin related protein; PIP3, phosphatidylinositol 3,4,5-triphosphate; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP5K, phosphatidylinositol 4-phosphate 5-kinase; IκB, inhibitor of NF-κB; IKK, IκB kinase; CARMA1, caspase recruitment domain membrane associated guanylate kinase protein-1; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; NIK, NF-κB-inducing kinase; STAT3, signal transducer and activator of transcription 3; MS, multiple sclerosis; RRMS, relapsing-remitting MS; Th, T helper; NOD, non-obese diabetic; EAE, experimental autoimmune encephalomyelitis; SH, Src homology; Itk, IL-2inducible kinase; PH, pleckstrin homology; PDK1, phosphoinositide-dependent protein kinase 1; PKB, protein kinase B; CD28SAbs, CD28 superagonistic antibodies.

* Corresponding author at: Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, via dei sardi 70, 00185 Rome, Italy.

E-mail address: loretta.tuosto@uniroma1.it (L. Tuosto).

This review illustrates the most relevant functional roles of CD28 in T cell activation and highlights the complex signalling motifs and mechanisms that define its TCR-dependent and TCR-independent functions. Moreover, some controversial data and unresolved functional roles of human and mouse CD28 are also discussed.

2. CD28 support to TCR-signalling

In the absence of CD28 signals, naïve T lymphocytes fail to activate and fall into a state of profound unresponsiveness, known as anergy, which is characterized by the inability to produce interleukin (IL)-2 and/or to proliferate [14,15]. On the contrary, CD28 engagement by either agonistic antibodies or its natural ligands B7.1/B7.2 lowers the T cell activation threshold [16] and leads to the augmentation of TCR signalling events necessary for efficient cytokine production (via augmented transcriptional activity and messenger RNA stabilization), cell cycle progression, survival, regulation of metabolism and T cell responses. This occurs as CD28 is a crucial player for immunological synapse (IS) organization, where it enhances close contact between T cells and APCs [17]. These events likely rely on CD28 “adhesion effects”, which are strongly dependent on CD28 capability to trigger actin cytoskeleton rearrangement events, which are necessary for the recruitment and the organization of molecular signalling complexes [18]. Particularly relevant for CD28-mediated costimulation of TCR signalling is the rearrangement of membrane lipid rafts [19], which generates a dynamic platform at the IS where many signalling proteins are concentrated and protected from phosphatases [20]. In this way, CD28 is able to act as a general amplifier of early TCR signalling pathways, such as tyrosine phosphorylation

events, phospholipase C γ 1 (PLC γ 1) activation and Ca $^{2+}$ response [17,19,21].

At a biochemical level, CD28 engagement leads to the recruitment and activation of several molecular adaptors and effector proteins that are essential for the optimal activation of the biochemical events triggered by TCR (Fig. 1) [8]. Briefly, one of the earliest events initiated by TCR recognition of peptide-MHC complexes is the tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs) of CD3 and ζ chains by Src family tyrosine kinases p56lck and p59fyn. Tyrosine phosphorylated ITAMs bind the Syk family tyrosine kinase Zap-70 that following activation by p56lck and/or p59fyn phosphorylates several important cellular proteins, thus inducing the activation of downstream signalling pathways. One critical substrate of ZAP-70 is the linker for activation of T cells (LAT) that following phosphorylation of specific tyrosine residues binds and recruits to the membrane PLC- γ 1 and the growth-factor receptor-bound protein (Grb2) [22].

PLC γ 1 hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP $_2$) into inositol-1,4,5-trisphosphate (IP $_3$) and diacylglycerol (DAG). Soluble IP $_3$ triggers intracellular Ca $^{2+}$ mobilization, thus leading to the activation of calcineurin and nuclear factor of activated T cells (NF-AT) [23]. Full PLC γ 1 activation strictly depends on CD28 signalling, as demonstrated by experiments in which TCR ligation in absence of costimulation results in a strong reduction of both PLC γ 1 phosphorylation and release of endoplasmic reticulum Ca $^{2+}$ into the cytoplasm [17]. The membrane lipid DAG activates the protein kinase C (PKC) θ and nuclear factor- κ B (NF- κ B) [24]. CD28 stimulation is essential to trigger the activation of the NF- κ B pathway by favouring the recruitment of PKC θ to the IS [25,26].




Fig. 1. CD28 amplifies early and downstream signalling pathways triggered by TCR. Upon TCR recognition of peptide-MHC complexes presented on the surface of APCs, Lck and Fyn phosphorylate CD3 and ζ chains, which bind ZAP-70. ZAP-70 phosphorylates LAT that in turn binds PLC- γ 1 that induces the activation of Ca $^{2+}$ /Calcineurin (CN) and NF-AT as well as PKC θ /CARMA1/Bcl10/MALT1 and NF- κ B; Grb2 that, by bringing SoS and Vav1, activates Ras/ERK and Rac-1/JNK, respectively, thus inducing AP-1; Grb2/Vav1 also activates Cdc42/WASP/Arp2/3 and actin cytoskeleton rearrangements necessary for the mobilization of membrane lipid rafts. NF-AT, NF- κ B and AP-1 cooperate to transactivate the IL-2 gene promoter.

Grb2 recruitment to LAT leads to the activation of the mitogen-activated protein kinase (MAPK) cascades. Indeed, Grb2 recruits Son of Seveless (SoS), a guanine nucleotide exchange factor for p21^{Ras}, that in turn activates the extracellular signal regulated kinases (ERK) pathway. Grb2 has been also implicated in the recruitment of Vav1, a guanine nucleotide exchange factor for small G proteins of the Rho family, Rac1 and Cdc42, and in the activation of Jun N terminal kinases (JNK). JNK and ERK cooperate to induce the transcriptional activation of AP-1 [27]. CD28 engagement by B7 cooperates with TCR for achieving the optimal activation of both ERK and JNK [21,28,29].

At a functional level, the most relevant outcomes of CD28 costimulation are the increase of T cell proliferation and cytokine production. CD28 strongly upregulates the expression of D cyclins by downregulating p27^{kip1} [30,31]. Moreover, during the G₀–G₁ transition, CD28 is also able to upregulate the biosynthesis of macromolecules and to increase energy metabolism by activating the mammalian target of rapamycin (mTOR), thus inducing the expression of genes involved in translation initiation, synthesis of ribosomal RNA and cell division [32].

In T cells, optimal induction of cell proliferation following the antigen encounter depends on the IL-2/IL-2 receptor system [33]. Notably, CD28 signals enhance IL-2 expression and secretion at both transcriptional and post-transcriptional levels [34,35]. The IL-2 promoter is, indeed, specifically regulated by NF-AT, NF-κB and AP-1 transcription factors that, as described above, are all amplified by CD28 (Fig. 1) [8]. In addition to the classical NF-AT, NF-κB and AP-1 binding sites, the IL-2 promoter contains a specific enhancer region, highly conserved between human and mouse, known as CD28-responsive element (CD28RE). CD28RE is a specific target sequence for CD28-regulated nuclear binding complex that together with adjacent NF-IL-2B AP-1 sites, is part of a composite element, termed RE/AP [36,37]. This regulative unit controls CD28 responsiveness in the IL-2 promoter and results in a site for signal integration, thus mutations of RE/AP strongly impair the transcriptional increase of IL-2 induced by CD28 costimulation. Moreover, the identification of specific NF-κB binding sites within the CD28RE of IL-2 promoter, highlighted the relevant role of NF-κB in CD28 costimulation [37].

Finally, CD28 controls the level of IL-2 secretion by means of post-transcriptional mechanisms that involve the enhancement of both export and stability of IL-2 mRNA [35,38,39]. mRNA stability is largely controlled by AU-rich elements contained within the 3' untranslated region (UTR) that affects mRNA degradation. In resting cells, AU-binding proteins, such as tristetraprolin, bind the 3'UTR of IL-2 mRNA and induce IL-2 mRNA degradation [40]. CD28 costimulation favours TCR-mediated nuclear export of NF90 that by binding the AU-rich elements increases IL-2 mRNA stability [38,39].

3. CD28 autonomous signalling: from cytoskeleton to NF-κB activation

Despite the relevance of CD28 in enhancing TCR-mediated activating signalling, CD28 is also able to act as a unique signalling receptor and to deliver TCR-independent autonomous signals [10,12,13], which finally lead to the regulation of both T cell survival [11,41] and cytokine production [9,42].

The unique nature of CD28 signalling strictly depends on its capability to promote cytoskeleton rearrangement events by recruiting Vav1 and filamin-A [43–46].

Vav1 is a critical guanine nucleotide exchange factor for Rac1 and Cdc42 and is required for CD28-dependent signals and actin nucleation [6,42,47,48]. Vav-1 is strongly tyrosine phosphorylated and activated by CD28 [47], binds CD28 following stimulation [43,49,50], thus bringing to the membrane the associated

noncatalytic region of tyrosine kinase (Nck) β [43,51], a critical adaptor that promotes N-Wiskott Aldrich syndrome protein (WASP)/actin related protein (Arp) 2/3 complex localization and actin polymerization [52]. The Arp2/3 complex in turn cooperates with filamins in establishing cortical actin architecture [53].

Filamins are large cytoplasmic proteins that crosslink cortical actin into a dynamic three-dimensional structure and, by interacting with more than 70 proteins involved in cell signalling [54], may represent versatile signalling scaffolds. Filamin-A is predominantly expressed in the immune system and participates in T cell activation [46,55]. CD28 recruits filamin-A to the membrane, where filamin-A cooperates with Vav1 to integrate signalling pathways resulting in actin polymerization, lipid raft mobilization and T cell activation [44,46].

The dynamic and organization of actin cytoskeleton is also tightly regulated by membrane phosphoinositides, which may directly interact with key actin binding proteins, thus controlling the selective localization of scaffolding molecules linking the actin cytoskeleton to the plasma membrane [56]. Among the phosphoinositides, the best regulators of the actin cytoskeleton are phosphatidylinositol 3,4,5-triphosphate (PIP3) and phosphatidylinositol 4,5-bisphosphate (PIP2), which are mainly generated by the activity of PI3K and phosphatidylinositol 4-phosphate 5-kinases (PIP5K), respectively [57]. CD28 recruits both class 1A PI3K and PIP5Kα and β, which in turn cooperate to generate the PIP2 and PIP3 levels necessary for filamin-A and Vav1 recruitments and activation as well as for promoting actin polymerization and CD28 signalling functions in human T lymphocytes [43,58,59].

The efforts made in an attempt to characterize the signalling pathways activated by CD28 in a TCR-independent manner, led to the identification of NF-κB as the most relevant CD28 biochemical target [42,60]. Since the first discovery of NF-κB binding sites within the CD28RE in the IL-2 promoter [37], a lot of efforts and progresses have been made to identify the mechanisms and molecules coupling CD28 to NF-κB activation.

3.1. NF-κB activation and CD28 pro-inflammatory functions

NF-κB family consists of five members that form homo and heterodimeric complexes including NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel. RelA, c-Rel and RelB contain transactivation domains and form transcriptionally active heterodimers in association with p50 and p52. Inhibitory proteins belonging to the inhibitor of NF-κB (IκB) family, which include IκBα, IκBβ, and IκBε regulate NF-κB activity. A protein kinase complex containing two serine kinases, IκB kinase (IKK)α and IKKβ and a third subunit, IKKγ/NEMO, with regulatory functions, phosphorylates IκBs, thus leading to their proteolytic degradation and release of NF-κB into the nucleus [61]. Two pathways have been described for NF-κB activation. The canonical pathway activates the tripartite IKKα/γ/β complex thus leading to phosphorylation-dependent IκB degradation and activation of RelA/p50 or c-Rel/p50 dimers. The non-canonical pathway activates IKKα homodimers, thus leading to the processing of NF-κB2 and the release of p52-containing heterodimers [62]. When co-engaged with TCR, CD28 contributes to the activation of the canonical pathway by recruiting PKCθ [25,26] and the ternary complex caspase recruitment domain membrane associated guanylate kinase protein 1 (CARMA1), Bcl10 and mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) that links TCR to the IKK complex [63–65]. MEKK1 has been also involved in the activation of the IKK complex by CD28 [66,67]. The main functional effect of CD28 contribution to TCR-induced NF-κB activation is the increase of IL-2 transcription [68–70].

Conversely, the stimulation of CD28 in the absence of TCR recruits and activates IKK α and a non-canonical NF- κ B2-like cascade leading to the nuclear translocation and activation of RelA/p52 dimers [11,45]. Vav-1 and filamin-A cooperates with CD28 to induce the activation of this non-canonical NF- κ B2-like cascade by binding and recruiting to the membrane IKK α [45] and the IKK α activator NF- κ B-inducing kinase (NIK) [44], respectively.

CD28 unique signalling to NF- κ B converges to the selective regulation of the expression of several genes, including anti- and pro-apoptotic gene of Bcl-2 family [41], the LTR of HIV-1 virus [71] and pro-inflammatory cytokine/chemokine [11]. The up-regulation of pro-inflammatory cytokines and chemokines by CD28 is particularly relevant in the context of inflammatory diseases, such as Multiple Sclerosis (MS), where we have recently observed that CD28 stimulation induces the selective up-regulation of IL-6, IL-21 and IL-17A expression in human primary T lymphocytes [9]. These cytokines are related to the T helper (Th) 17 cell phenotype [72] and have been found at higher levels in relapsing-remitting MS (RRMS) patients during exacerbations or undergoing a relapse [73,74]. The use of specific inhibitory drugs evidenced that the up-regulation of pro-inflammatory cytokines was dependent on CD28-associated class 1A PI3K activation [9,59]. The PI3K pathway plays a central role in regulating inflammation and its dysfunctions could be linked to the development of autoimmunity [75]. PI3K has been also involved in activating mTOR pathways, which govern Th17 differentiation [76,77]. All these data strongly suggest that CD28 may modulate the metabolic processes, which regulate specific pro-inflammatory T cell responses and the amplification of Th17 cells in inflammatory/autoimmune diseases. For instance, several mouse models of human inflammatory/autoimmune diseases, such as autoimmune diabetes in Non-obese diabetic (NOD) mice [78], MS in experimental autoimmune

encephalomyelitis (EAE) mice [79] or systemic autoimmune disorders [80,81] have evidenced the relevance of CD28 costimulatory signals.

4. CD28 signalling motifs

CD28 signalling properties derives from tyrosine and proline-based motifs within its small cytoplasmic domain (41 aa), which bind the Src homology (SH) 2 and SH3 domain of intracellular signalling molecules. It contains a N-terminal YNMN motif that following phosphorylation binds the SH2 domain of the p85 subunit of class 1A PI3K and the adaptor proteins Grb2 and Grb2-related adaptor downstream of Shc (GADS) [8,82]. Downstream of the YNMN motif, CD28 has two proline-rich regions, the N-terminal PRRP that binds the SH3 domain of the IL-2 inducible kinase (Itk) [83], and a C-terminal motif PYAP that binds Lck [84,85], Grb2 [86], filamin-A and associated NIK [44,46], Vav1 and associated PIP5K α and β [43,58].

4.1. The CD28-YNMN motif and PI3K-dependent functional properties

Engagement of CD28 by either agonistic antibodies or its natural ligands induces the tyrosine phosphorylation of YNMN, likely mediated by p56lck and p59fyn [87,88], that in turn binds the SH2 domain of p85 subunit of class 1A PI3K [89–92]. Class 1A PI3K phosphorylates PIP2 and generates PIP3 lipids that bind the pleckstrin homology (PH) domains of important signalling intermediates, such as phosphoinositide-dependent protein kinase 1 (PDK1), protein kinase B (PKB/AKT) and Vav1 [93]. PDK1 association with CARMA1 leads to the membrane recruitment of PKC θ [94] that is activated by PDK1 through phosphorylation on threonine 538 [26]. PKC θ co-segregates with CD28 to a




Fig. 2. Schematic model of human CD28-mediated activation of actin cytoskeleton rearrangement, non-canonical NF- κ B pathway and pro-inflammatory cytokine/chemokine gene expression. Following engagement of human CD28 by B7, tyrosine phosphorylated YNMN binds the SH2 domain of p85 regulatory subunit of class 1A PI3K and tyrosine phosphorylated C-terminal YAPP binds Vav1 and associated PIP5K α and Nck. PIP5K α generates PIP2 that favours the recruitment of WASP/Cdc42/Arp2/3 complexes and Vav1/Nck complexes induce actin cytoskeleton reorganization and the recruitment of the actin binding protein filamin-A (FLNa) and associated NIK. Class 1A PI3K phosphorylates PIP2 and generates PIP3 that favours the recruitment and activation of Akt. Akt cooperates with NIK to activate IKK α and non-canonical p52/RelA NF- κ B pathway, thus leading to the transcription of pro-inflammatory cytokine/chemokine genes.

spatially unique subregion within the IS [95], where it favours the activation of CARMA1/Bcl10/MALT1 complex and IKKs [65]. PDK1 recruitment to the membrane also leads to the phosphorylation of Akt on threonine 308 [96,97], thereby favouring its activation. Once activated Akt cooperates with PKC θ in stimulating the NF- κ B cascade [98]. For instance, Akt promotes TCR/CD28-mediated phosphorylation of Bcl10 and binding to CARMA1 [99]. In addition to cooperate with CD28 and PKC θ in activating the canonical NF- κ B pathway [100,101], Akt synergizes with CD28 to phosphorylate Cot/TPL2 at serine 400 [102], thus leading to NIK-dependent activation of IKK α [103–105].

At a functional level, PI3K-dependent activation of Akt has been found to regulate the expression of survival [100,106,107], IL-2 and inflammatory genes [9,42]. The PI3K/Akt pathway enhances IL-2 secretion by inhibiting the nuclear export of NF-AT via glycogen synthase kinase 3 phosphorylation [108] and by favouring glucose metabolism required for DNA, RNA and protein synthesis [32]. More recent data evidenced a crucial role of PI3K/Akt pathway in favouring the phosphorylation of IL-6/IL21-associated signal transducer and activator of transcription 3 (STAT3) and IL-17A gene expression [76]. These results together with our data that CD28-mediated up-regulation of IL-6, IL-21 and IL-17A in MS patients is dependent on PI3K activation [9], also suggest a role of PI3K/Akt pathway in regulating CD28 unique pro-inflammatory functions (Fig. 2).

Importantly, recent data from knocking mice evidenced that mutations of the proximal YMMN motif and abrogation of PI3K binding has no detectable effects *in vivo* [109], thus suggesting the existence of differences between mice and human CD28 signalling properties (see below).

4.2. CD28 and the C-terminal proline rich motifs

In addition to the YMMN motif, CD28 intracytoplasmic tail contains two proline-rich motifs: a N-terminal P¹⁹⁶RRP (numbering in human CD28) that binds the SH3 domain I κ k [83,110] and a C-terminal proline-P²⁰⁸YAP (numbering in human CD28; P¹⁸⁷YAP in mouse) that recruits several important signalling proteins. While the function of P¹⁹⁶RRP and I κ k in CD28 costimulation is still unclear [111–113], the PYAP motif is undoubtedly a key regulator of CD28 signalling functions. C-terminal PYAP motif was originally reported to bind the SH3 domain Lck [84], thus sustaining its kinase activity and favouring lipid raft recruitment to the IS [85].

More recent studies revealed an important contribution of the C-terminal PYAP motif in regulating the localization of CD28 at IS [114]. Yokosuka et al. evidenced that the PYAP motif regulates the recruitment of PKC θ to the IS and its colocalization with CD28 [95]. Tavano et al. found that this motif is also important for filamin-A recruitment [46], thus suggesting a critical role of PYAP motif in regulating both canonical [95] and non-canonical NF- κ B pathways [44]. Indeed, Watanabe et al. reported that the substitution of the two proline residues in the C-terminal PYAP motif of murine CD28 strongly reduces NF- κ B transcriptional activity [115]. Furthermore, we found that mutations of tyrosine residues within human C-terminal YQPYAPP also result in impaired IKK α activation and NF- κ B-dependent transcription of target genes, thus suggesting the involvement of SH2 binding motifs [43,44,46,71].

Vav1 is the critical regulator that couples the C-terminal PYAP of CD28 to the activation of downstream signalling pathways. Vav1 recruitment to the C-terminal PYAP of CD28 is, indeed, essential for CD28 autonomous signalling leading to NF-AT, NF- κ B and IL-2/IL-4 transcription [12,45,116]. On the basis of the ability of the adapter molecules Grb2 to interact with both CD28 [86,117] and Vav1 [118,119], Grb2 binding to CD28 has been suggested as the mechanism by which CD28 recruits Vav1 [49,50]. However, when we looked at Grb2 recruitment to CD28 in human primary CD4⁺ T cells, we did not find any association between CD28 and Grb2 [43]. Conversely, we found that, in human primary CD4⁺ T cells stimulated by B7, CD28 associates with Vav1 through its C-terminal PYAPP in an SH2-dependent manner [43]. Moreover, we also demonstrated that the cooperative signalling function of Vav1 relies on its ability to promote the actin polymerization events required for the efficient recruitment and activation of essential signalling complexes to CD28. For instance, by binding the C-terminal YAPP motif of human CD28, Vav1 favours the recruitment of associated Nck β [51] and PIP5K α/β [43,58]. PIP5Ks in turn synthesize PIP2 lipids that synergize with Nck β in promoting N-WASP-dependent actin rearrangements [120] and the recruitment of filamin-A and associated NIK [44,46], thus inducing NF- κ B-dependent pro-survival and pro-inflammatory gene expressions (Fig. 2).

5. Signalling differences between human and mouse CD28

Until 2006, the signalling properties of CD28 between rodent (mouse and rat) and human were considered rather similar. For

Table 1
CD28 superagonistic antibodies in experimental models.

Antibody	Species	Functional properties
JJ316	Rat	Stimulating in the absence of TCR No pro-inflammatory effects Expand regulatory T cells Prevents EAE
D665	Mouse	Stimulating in the absence of TCR No pro-inflammatory effects Expand regulatory T cells Protect from EAE and GVHD
5.11A1	Humanized Mouse	Stimulating in the absence of TCR No pro-inflammatory functions Increases thymic cellularity Induces peripheral T cell depletion
TGN412	Human	Stimulating in the absence of TCR Pro-inflammatory functions Induces severe systemic inflammatory cytokines release
	Monkey	Stimulating in the absence of TCR No pro-inflammatory effects Does not induce severe systemic inflammatory cytokines release

EAE, experimental autoimmune encephalomyelitis; GVHD, graft-versus-host-disease.




Fig. 3. The sequence and signalling molecules recruited to human and mouse CD28 cytoplasmic motifs. The sequence of SH3 and SH2 binding motifs within human and mouse cytoplasmic tails of CD28 is shown. The YMNMT motif binds the SH2 of p85 subunit of class 1A PI3K in both human and mouse as well as Grb2/Vav1 complexes in mouse. The N-terminal PRRP motif binds the SH3 domain of Itk in both human and mouse. The C-terminal PYAP motif binds the SH3 domain of Lck in both human and mouse, Grb2 in mouse, and filamin-A (FLNa) in human. Tyrosine phosphorylated C-terminal YAPP of human CD28 is a consensus sequence for the SH2 domain of Vav1 and binds Vav1.

instance, in both human and mouse, CD28 cooperates with TCR in activating PKC θ , PLC γ 1, ERK and JNK kinases, thus leading to the transcriptional activation of NF-AT, AP-1 and NF- κ B transcription factors at a similar extent [6,8,112,121]. As a consequence, for several years, *in vivo* mouse models have been used for understanding the mechanisms of T lymphocyte activation and differentiation and the role of CD28 costimulation in health and immune diseases. Thus, when CD28 superagonistic antibodies (CD28SABs) were discovered to preferentially activate and expand immunosuppressive regulatory T cells [122], an enormous amount of pre-clinical experiments have been performed to evaluate the potential use of these CD28SABs to ameliorate the onset, progression and clinical course of human autoimmune diseases (Table 1). However, when a humanized CD28SAB (TGN1412) was administered to volunteers on March 2006, the phase I clinical trial turned in a catastrophe, because this antibody induced a rapid and massive cytokine production (i.e. IFN- γ , IL-1, IL-6, TNF- α), thus causing a severe systemic inflammatory response syndrome [123]. Altogether, the above reported data evidenced that the translation of experimental results from mice to men could determine dramatic effects, supporting differences in CD28 signalling capabilities between human and mouse [124,125].

The comparison of the sequence in the cytoplasmic tail of CD28 between human and both mouse and rat reveals a single amino acid substitution within the C-terminal proline rich motif: P²¹² in human CD28 Vs A¹⁹¹ in mouse and rat (Fig. 3). Although, this mutation does not affect the proline consensus sequence for SH3 binding, it may change a putative SH2 binding consensus sequence. For instance, Y²⁰⁹APP²¹² within the C-terminal proline rich motif of CD28 is quite similar to different consensus sequences identified as optimal binding sites for the SH2 of Vav1 [126–130]. Our data on the loss of CD28/Vav1 interaction by mutating the tyrosine residues within the C-terminal proline rich motif of CD28

[43] together with our recent observations that mutation in the SH2 domain of Vav1 or P²¹² to A substitution within CD28 impairs both NF- κ B activation and pro-inflammatory cytokine expression (Tuosto's personal communication), strongly support a role for YAPP sequence and Vav1 binding in mediating the functional differences observed between human and mouse CD28 (Fig. 3).

In conclusion, despite the enormous progresses made on CD28 costimulatory functions in T lymphocytes, the molecular mechanisms of CD28 signalling are not completely understood. A deeper understanding of the signalling properties of human CD28 will provide new avenues for the design of appropriate therapeutic drugs targeting CD28-associated signalling pathways for autoimmune/inflammatory disorders.

Conflict of interest

The authors have no financial conflicts of interest.

Acknowledgments

The work was supported by Progetto Ateneo" (Sapienza University of Rome, Italy) and Multiple Sclerosis Italian Foundation (FISM- 2011/R/36).

References

- [1] A. Aruffo, B. Seed, Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system, Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 8573–8577.
- [2] J.A. Gross, T. St John, J.P. Allison, The murine homologue of the T lymphocyte antigen CD28: molecular cloning and cell surface expression, J. Immunol. 144 (1990) 3201–3210.
- [3] G.J. Freeman, J.G. Gribben, V.A. Boussiotis, J.W. Ng, V.A. Restivo Jr., L.A. Lombard, et al., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation, Science 262 (1993) 909–911.

- [4] P.S. Linsley, J.L. Greene, W. Brady, J. Bajorath, J.A. Ledbetter, R. Peach, Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors, *Immunity* 1 (1994) 793–801.
- [5] S. Yao, Y. Zhu, G. Zhu, M. Augustine, L. Zheng, D.J. Goode, et al., B7-h2 is a costimulatory ligand for CD28 in human, *Immunity* 34 (2011) 729–740.
- [6] O. Acuto, F. Michel, CD28-mediated co-stimulation: a quantitative support for TCR signalling, *Nat. Rev. Immunol.* 3 (2003) 939–951.
- [7] S.P. Manickasingham, S.M. Anderton, C. Burkhart, D.C. Wraith, Qualitative and quantitative effects of CD28/B7-mediated costimulation on naive T cells in vitro, *J. Immunol.* 161 (1998) 3827–3835.
- [8] J.S. Boomer, J.M. Green, An enigmatic tail of CD28 signaling, *Cold Spring Harb Perspect Biol.* 2 (2010) a002436.
- [9] C. Camperio, M. Muscolini, E. Volpe, D. Di Mitri, R. Mechelli, M.C. Buscarinu, et al., CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes, *Immunol. Lett.* 158 (2014) 134–142.
- [10] M. Diehn, A.A. Alizadeh, O.J. Rando, C.L. Liu, K. Stankunas, D. Botstein, et al., Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation, *Proc. Natl. Acad. Sci. U. S. A.* 99 (2002) 11796–11801.
- [11] B. Marinari, A. Costanzo, V. Marzano, E. Piccolella, L. Tuosto, CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters, *Proc Natl Acad Sci U. S. A.* 101 (2004) 6098–6103.
- [12] M. Raab, S. Pfister, C.E. Rudd, CD28 signaling via VAV/SLP-76 adaptors: regulation of cytokine transcription independent of TCR ligation, *Immunity* 15 (2001) 921–933.
- [13] J.L. Riley, M. Mao, S. Kobayashi, M. Biery, J. Burchard, G. Cavet, et al., Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors, *Proc. Natl. Acad. Sci. U. S. A.* 99 (2002) 11790–11795.
- [14] R.H. Schwartz, T cell anergy, *Annu. Rev. Immunol.* 21 (2003) 305–334.
- [15] F.A. Harding, J.G. McArthur, J.A. Gross, D.H. Raulet, J.P. Allison, CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones, *Nature.* 356 (1992) 607–609.
- [16] A. Viola, A. Lanzavecchia, T cell activation determined by T cell receptor number and tunable thresholds, *Science* 273 (1996) 104–106.
- [17] F. Michel, G. Attal-Bonnefoy, G. Mangino, S. Mise-Omata, O. Acuto, CD28 as a molecular amplifier extending TCR ligation and signaling capabilities, *Immunity* 15 (2001) 935–945.
- [18] O. Acuto, D. Cantrell, T cell activation and the cytoskeleton, *Annu. Rev. Immunol.* 18 (2000) 165–184.
- [19] A. Viola, S. Schroeder, Y. Sakakibara, A. Lanzavecchia, T lymphocyte costimulation mediated by reorganization of membrane microdomains, *Science* 283 (1999) 680–682.
- [20] A. Viola, R.L. Contento, B. Molon, Signaling amplification at the immunological synapse, *Curr. Top. Microbiol. Immunol.* 340 (2010) 109–122.
- [21] L. Tuosto, O. Acuto, CD28 affects the earliest signaling events generated by TCR engagement, *Eur. J. Immunol.* 28 (1998) 2132–2142.
- [22] W. Zhang, L.E. Samelson, The role of membrane-associated adaptors in T cell receptor signalling, *Semin. Immunol.* 12 (2000) 35–41.
- [23] Y. Gwack, S. Feske, S. Srikanth, P.G. Hogan, A. Rao, Signalling to transcription: store-operated Ca²⁺ entry and NFAT activation in lymphocytes, *Cell Calcium* 42 (2007) 145–156.
- [24] Y. Li, C.E. Sedwick, J. Hu, A. Altman, Role for protein kinase C θ (PKC θ) in TCR/CD28-mediated signaling through the canonical but not the non-canonical pathway for NF-kappaB activation, *J. Biol. Chem.* 280 (2005) 1217–1223.
- [25] Z. Sun, C.W. Arendt, W. Ellmeier, E.M. Schaeffer, M.J. Sunshine, L. Gandhi, et al., PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes, *Nature* 404 (2000) 402–407.
- [26] M. Villalba, K. Bi, J. Hu, Y. Altman, P. Pushway, E. Reits, et al., Translocation of PKC[theta] in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C, *J. Cell Biol.* 157 (2002) 253–263.
- [27] L.P. Kane, J. Lin, A. Weiss, Signal transduction by the TCR for antigen, *Curr. Opin. Immunol.* 12 (2000) 242–249.
- [28] J.A. Nunes, M. Battifora, J.R. Woodgett, A. Truneh, D. Olive, D.A. Cantrell, CD28 signal transduction pathways. A comparison of B7-1 and B7-2 regulation of the map kinases: ERK2 and Jun kinases, *Mol. Immunol.* 33 (1996) 3–70.
- [29] B. Su, E. Jacinto, M. Hibi, T. Kallunki, M. Karin, Y. Ben-Neriah, JNK is involved in signal integration during costimulation of T lymphocytes, *Cell* 77 (1994) 727–736.
- [30] L.J. Appleman, A.A. van Puijenbroek, K.M. Shu, L.M. Nadler, V.A. Boussiotis, CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells, *J. Immunol.* 168 (2002) 2729–2736.
- [31] G.J. Boonen, A.M. van Dijk, L.F. Verdonck, R.A. van Lier, G. Rijksen, R.H. Medema, CD28 induces cell cycle progression by IL-2-independent down-regulation of p27kip1 expression in human peripheral T lymphocytes, *Eur. J. Immunol.* 29 (1999) 789–798.
- [32] K.A. Frauwirth, J.L. Riley, M.H. Harris, R.V. Parry, J.C. Rathmell, D.R. Plas, et al., The CD28 signaling pathway regulates glucose metabolism, *Immunity* 16 (2002) 769–777.
- [33] H.P. Kim, J. Imbert, W.J. Leonard, Both integrated and differential regulation of components of the IL-2/IL-2 receptor system, *Cytokine Growth Factor Rev.* 17 (2006) 349–366.
- [34] J.D. Fraser, B.A. Irving, G.R. Crabtree, A. Weiss, Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28, *Science* 251 (1991) 313–316.
- [35] T. Lindstein, C.H. June, J.A. Ledbetter, G. Stella, C.B. Thompson, Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway, *Science* 244 (1989) 339–343.
- [36] V.S. Shapiro, K.E. Truitt, J.B. Imboden, A. Weiss, CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites, *Mol. Cell. Biol.* 17 (1997) 4051–4058.
- [37] C.L. Verweij, M. Geerts, L.A. Aarden, Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element, *J. Biol. Chem.* 266 (1991) 14179–14182.
- [38] Y. Pei, P. Zhu, Y. Dang, J. Wu, X. Yang, B. Wan, et al., Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation, *J. Immunol.* 180 (2008) 222–229.
- [39] J. Shim, H. Lim, J.R. Yates, M. Karin, Nuclear export of NF90 is required for interleukin-2 mRNA stabilization, *Mol. Cell* 10 (2002) 1331–1344.
- [40] R.L. Ogilvie, M. Abelson, H.H. Hau, I. Vlasova, P.J. Blackshear, P.R. Bohjanen, Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay, *J. Immunol.* 174 (2005) 953–961.
- [41] R. Cianfrocca, M. Muscolini, V. Marzano, A. Annibaldi, B. Marinari, M. Levrero, et al., RelA/NF-kappaB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells, *Cell Death Differ.* 15 (2008) 354–363.
- [42] L. Tuosto, NF-kappaB family of transcription factors: biochemical players of CD28 co-stimulation, *Immunol. Lett.* 135 (2011) 1–9.
- [43] M. Muscolini, C. Camperio, N. Porciello, S. Caristi, C. Capuano, A. Viola, et al., Phosphatidylinositol 4-phosphate 5-kinase alpha and vav1 mutual cooperation in cd28-mediated actin remodeling and signaling functions, *J. Immunol.* 194 (2015) 1323–1333.
- [44] M. Muscolini, A. Sajeve, S. Caristi, L. Tuosto, A novel association between filamin A and NF-kappaB inducing kinase couples CD28 to inhibitor of NF-kappaB kinase alpha and NF-kappaB activation, *Immunol. Lett.* 36 (2011) 203–212.
- [45] E. Piccolella, F. Spadaro, C. Ramoni, B. Marinari, A. Costanzo, M. Levrero, et al., Vav-1 and the IKK alpha subunit of I kappa B kinase functionally associate to induce NF-kappa B activation in response to CD28 engagement, *J. Immunol.* 170 (2003) 2895–2903.
- [46] R. Tavano, R.L. Contento, S.J. Baranda, M. Soligo, L. Tuosto, S. Manes, et al., CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse, *Nat. Cell. Biol.* 8 (2006) 1270–1276.
- [47] F. Michel, O. Acuto, CD28 costimulation: a source of Vav-1 for TCR signaling with the help of SLP-76? *Sci. STKE* 144 (2002) pe35.
- [48] C.E. Rudd, M. Raab, Independent CD28 signaling via VAV and SLP-76: a model for in trans costimulation, *Immunol. Rev.* 192 (2003) 32–41.
- [49] H. Schneider, C.E. Rudd, CD28 and Grb-2, relative to Gads or Grap, preferentially co-operate with Vav1 in the activation of NFAT/AP-1 transcription, *Biochem. Biophys. Res. Commun.* 369 (2008) 616–621.
- [50] Y.R. Thaker, H. Schneider, C.E. Rudd, TCR and CD28 activate the transcription factor NF-kappaB in T-cells via distinct adaptor signaling complexes, *Immunol. Lett.* 163 (2015) 113–119.
- [51] M. Barda-Saad, N. Shirasu, M.H. Pauker, N. Hassan, O. Perl, A. Balbo, et al., Cooperative interactions at the SLP-76 complex are critical for actin polymerization, *EMBO J.* 29 (2010) 2315–2328.
- [52] M. Lettau, J. Pieper, O. Janssen, Nck adapter proteins: functional versatility in T cells, *Cell. Commun. Signal.* 7 (2009) 1.
- [53] T.P. Stoszel, J. Condeelis, L. Cooley, J.H. Hartwig, A. Noegel, M. Schleicher, et al., Filamins as integrators of cell mechanics and signalling, *Nat. Rev. Mol. Cell Biol.* 2 (2001) 138–145.
- [54] A.X. Zhou, J.H. Hartwig, L.M. Akyurek, Filamins in cell signaling, transcription and organ development, *Trends Cell Biol.* 20 (2010) 113–123.
- [55] K. Hayashi, A. Altman, Filamin A is required for T cell activation mediated by protein kinase C-theta, *J. Immunol.* 177 (2006) 1721–1728.
- [56] J. Saarikangas, H. Zhao, P. Lappalainen, Regulation of the actin cytoskeleton-plasma membrane interplay by phosphoinositides, *Physiol. Rev.* 90 (2010) 259–289.
- [57] L. Tuosto, C. Capuano, M. Muscolini, A. Santoni, R. Galandrini, The multifaceted role of PIP2 in leukocyte biology, *Cell. Mol. Life Sci.* 72 (2015) 4461–4474.
- [58] M. Kallikourdis, A.E. Trovato, G. Roselli, M. Muscolini, N. Porciello, L. Tuosto, et al., Phosphatidylinositol 4-phosphate 5-kinase β controls recruitment of lipid rafts into the immunological synapse, *J. Immunol.* 2016 (196) (2016) 1955–1963.
- [59] M. Muscolini, C. Camperio, C. Capuano, S. Caristi, E. Piccolella, R. Galandrini, et al., Phosphatidylinositol 4-phosphate 5-kinase alpha activation critically contributes to CD28-dependent signaling responses, *J. Immunol.* 190 (2013) 5279–5286.
- [60] M.L. Schmitz, D. Krappmann, Controlling NF-kappaB activation in T cells by costimulatory receptors, *Cell Death Differ.* 13 (2006) 834–842.
- [61] S. Vallabhapurapu, M. Karin, Regulation and function of NF-kappaB transcription factors in the immune system, *Annu. Rev. Immunol.* 27 (2009) 693–733.
- [62] J.L. Luo, H. Kamata, M. Karin, IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy, *J. Clin. Invest.* 115 (2005) 2625–2632.

- [63] F. Rebeaud, S. Hailfinger, A. Posevitz-Fejfar, M. Tapernoux, R. Moser, D. Rueda, et al., The proteolytic activity of the paracaspase MALT1 is key in T cell activation, *Nat. Immunol.* 9 (2008) 272–281.
- [64] M.J. Tanner, W. Hanel, S.L. Gaffen, X. Lin, CARMA1 coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor-induced NF-kappaB activation, *J. Biol. Chem.* 282 (2007) 17141–17147.
- [65] D. Wang, R. Matsumoto, Y. You, T. Che, X.Y. Lin, S.L. Gaffen, et al., CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkkappaB kinase beta to the immunological synapse through CARMA1, *Mol. Cell. Biol.* 24 (2004) 164–171.
- [66] B. Marinari, A. Costanzo, A. Viola, F. Michel, G. Mangino, O. Acuto, et al., Vav cooperates with CD28 to induce NF-kappaB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1, *Eur. J. Immunol.* 32 (2002) 447–456.
- [67] L. Tuosto, A. Costanzo, F. Guido, B. Marinari, S. Vossio, F. Moretti, et al., Mitogen-activated kinase kinase kinase 1 regulates T cell receptor- and CD28-mediated signaling events which lead to NF-kappaB activation, *Eur. J. Immunol.* 30 (2000) 2445–2454.
- [68] E.W. Harhaj, S.C. Sun, IkkappaB kinases serve as a target of CD28 signaling, *J. Biol. Chem.* 273 (1998) 25185–25190.
- [69] J.H. Lai, T.H. Tan, CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin, *J. Biol. Chem.* 269 (1994) 30077–30080.
- [70] M. Sanchez-Lockhart, E. Marin, B. Graf, R. Abe, Y. Harada, C.E. Sedwick, et al., Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways, *J. Immunol.* 173 (2004) 7120–7124.
- [71] A. Annibaldi, A. Sajevo, M. Muscolini, F. Ciccocanti, M. Corazzari, M. Piacentini, et al., CD28 ligation in the absence of TCR promotes RelA/NF-kB recruitment and trans-activation of the HIV-1 LTR, *Eur. J. Immunol.* 38 (2008) 1446–1451.
- [72] F. Jadidi-Niaragh, A. Mirshafiey, Th17 cell, the new player of neuroinflammatory process in multiple sclerosis, *Scand. J. Immunol.* 74 (2011) 1–13.
- [73] L.J. Edwards, B. Sharrack, A. Ismail, H. Tumani, C.S. Constantinescu, Central inflammation versus peripheral regulation in multiple sclerosis, *J. Neurol.* 258 (2011) 1518–1527.
- [74] M.C. Ysraaelit, M.I. Gaitan, A.S. Lopez, J. Correale, Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis, *Neurology* 71 (2008) 1948–1954.
- [75] A. Ghigo, F. Damilano, L. Braccini, E. Hirsch, PI3 K inhibition in inflammation: Toward tailored therapies for specific diseases, *Bioessays* 32 (2010) 185–196.
- [76] G.M. Delgoffe, K.N. Pollizzi, A.T. Waickman, E. Heikamp, D.J. Meyers, M.R. Horton, et al., The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2, *Nat. Immunol.* 12 (2011) 295–303.
- [77] L.Z. Shi, R. Wang, G. Huang, P. Vogel, G. Neale, D.R. Green, et al., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells, *J. Exp. Med.* 208 (2011) 1367–1376.
- [78] D.J. Lenschow, K.C. Herold, L. Rhee, B. Patel, A. Koons, H.Y. Qin, et al., CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes, *Immunity* 5 (1996) 285–293.
- [79] S.D. Miller, C.L. Vanderlugt, D.J. Lenschow, J.G. Pope, N.J. Karandikar, M.C. Dal Canto, et al., Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE, *Immunity* 3 (1995) 739–745.
- [80] K.M. Pollard, M. Arnush, P. Hultman, D.H. Kono, Costimulation requirements of induced murine systemic autoimmune disease, *J. Immunol.* 173 (2004) 5880–5887.
- [81] X. Tai, F. Van Laethem, A.H. Sharpe, A. Singer, Induction of autoimmune disease in CTLA-4^{-/-} mice depends on a specific CD28 motif that is required for in vivo costimulation, *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 13756–13761.
- [82] P. Riha, C.E. Rudd, CD28 co-signaling in the adaptive immune response, *Self Nonself* 1 (2010) 231–240.
- [83] L.E. Marengère, K. Okkenhaug, A. Clavreul, D. Couez, S. Gibson, G.B. Mills, et al., The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28, *J. Immunol.* 159 (1997) 3220–3229.
- [84] A.D. Holdford, J.M. Green, S.D. Levin, M.F. Denny, D.B. Straus, P.S. Link, et al., Proline residues in CD28 and the Src homology (SH) 3 domain of Lck are required for T cell costimulation, *J. Exp. Med.* 190 (1999) 375–384.
- [85] R. Tavano, G. Gri, B. Molon, B. Marinari, C.E. Rudd, L. Tuosto, et al., CD28 and lipid rafts coordinate recruitment of Lck to the immunological synapse of human T lymphocytes, *J. Immunol.* 173 (2004) 5392–5397.
- [86] H.H. Kim, M. Tharayil, C.E. Rudd, Growth factor receptor-bound protein 2 SH2/SH3 domain binding to CD28 and its role in co-signaling, *J. Biol. Chem.* 273 (1998) 296–301.
- [87] P.D. King, A. Sadra, J.M. Teng, L. Xiao-Rong, A. Han, A. Selvakumar, et al., Analysis of CD28 cytoplasmic tail tyrosine residues as regulators and substrates for the protein tyrosine kinases, EMT and LCK, *J. Immunol.* 158 (1997) 580–590.
- [88] M. Raab, Y.C. Cai, S.C. Bunnell, S.D. Heyeck, L.J. Berg, Rudd CE. p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase Itk: implications for T-cell costimulation, *Proc. Natl. Acad. Sci. U. S. A.* 92 (1995) 8891–8895.
- [89] A. August, B. Dupont, CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase, *Int. Immunol.* 6 (1994) 769–774.
- [90] Y.C. Cai, D. Cefai, H. Schneider, M. Raab, N. Nabavi, C.E. Rudd, Selective CD28pYMMN mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation, *Immunity* 3 (1995) 417–426.
- [91] F. Pages, M. Ragueneau, R. Rottapel, A. Truneh, J. Nunes, J. Imbert, et al., Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling, *Nature* 369 (1994) 327–329.
- [92] K.V. Prasad, Y.C. Cai, M. Raab, B. Duckworth, L. Cantley, S.E. Shoelson, et al., T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 2834–2838.
- [93] M.A. Lemmon, Pleckstrin homology domains: two halves make a hole, *Cell* 120 (2005) 574–576.
- [94] K.Y. Lee, F. D'Acquisto, M.S. Hayden, J.H. Shim, S. Ghosh, PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation, *Science* 308 (2005) 114–118.
- [95] T. Yokosuka, W. Kobayashi, K. Sakata-Sogawa, M. Takamatsu, A. Hashimoto-Tane, M.L. Dustin, et al., Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation, *Immunity* 29 (2008) 589–601.
- [96] K. Okkenhaug, D.T. Patton, A. Bilancio, F. Garcon, W.C. Rowan, B. Vanhaesebroeck, The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells, *J. Immunol.* 177 (2006) 5122–5128.
- [97] S.G. Park, J. Schulze-Luehrman, M.S. Hayden, N. Hashimoto, W. Ogawa, M. Kasuga, et al., The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells, *Nat. Immunol.* 10 (2009) 158–166.
- [98] B. Bauer, N. Krumbock, F. Fresser, F. Hochholdinger, M. Spitaler, A. Simm, et al., Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells, *J. Biol. Chem.* 276 (2001) 31627–31634.
- [99] P. Narayan, B. Holt, R. Tosti, L.P. Kane, CARMA1 is required for Akt-mediated NF-kappaB activation in T cells, *Mol. Cell. Biol.* 26 (2006) 2327–2336.
- [100] L.P. Kane, P.G. Abdres, K.C. Howland, A.K. Abbas, A. Weiss, Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not Th2 cytokines, *Nat. Immunol.* 2 (2001) 37–44.
- [101] R.V. Parry, G. Reif, D.M. Smith, B.A. Sanson, B.A. Hemmings, S.G. Ward, Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase B, *Eur. J. Immunol.* 27 (1997) 2495–2501.
- [102] L.P. Kane, M.N. Mollenauer, Z. Xu, C.W. Turck, A. Weiss, Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription, *Mol. Cell. Biol.* 22 (2002) 5962–5974.
- [103] X. Lin, E.T. Cunningham Jr., Y. Mu, R. Gelezianus, W.C. Greene, The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkkappaB kinases, *Immunity* 10 (1999) 271–280.
- [104] C. Sanchez-Valdepenas, A.G. Martin, P. Ramakrishnan, D. Wallach, M. Fresno, NF-kappaB-inducing kinase is involved in the activation of the CD28 responsive element through phosphorylation of c-Rel and regulation of its transactivating activity, *J. Immunol.* 176 (2006) 4666–4674.
- [105] C. Sanchez-Valdepenas, C. Punzon, B. San-Antonio, A.G. Martin, M. Fresno, Differential regulation of p65 and c-Rel NF-kappaB transactivating activity by Cot, protein kinase C zeta and NIK protein kinases in CD3/CD28 activated T cells, *Cell. Signal.* 19 (2007) 528–537.
- [106] J.S. Burr, N.D. Savage, G.E. Messah, S.L. Kimzey, A.S. Shaw, R.H. Arch, et al., Cutting edge: distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-XL, *J. Immunol.* 166 (2001) 5331–5335.
- [107] R.G. Jones, M. Parsons, M. Bonnard, V.S. Chan, W.C. Yeh, J.R. Woodgett, et al., Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo, *J. Exp. Med.* 191 (2000) 1721–1734.
- [108] C.R. Beals, C.M. Sheridan, C.W. Turck, P. Gardner, G.R. Crabtree, Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3, *Science* 275 (1997) 1930–1934.
- [109] L.F. Dodson, J.S. Boomer, C.M. Deppong, D.D. Shah, J. Sim, T.L. Bricker, et al., Targeted knock-in mice expressing mutations of CD28 reveal an essential pathway for costimulation, *Mol. Cell. Biol.* 29 (2009) 3710–3721.
- [110] A. August, S. Gibson, Y. Kawakami, T. Kawakami, G.B. Mills, B. Dupont, CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase Itk/EMT in the human Jurkat leukemic T-cell line, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 9347–9351.
- [111] C.R. Li, L.J. Berg, Itk is not essential for CD28 signaling in naive T cells, *J. Immunol.* 174 (2005) 4475–4479.
- [112] C.E. Rudd, A. Taylor, H. Schneider, CD28 and CTLA-4 coreceptor expression and signal transduction, *Immunol. Rev.* 229 (2009) 12–26.
- [113] W.C. Yang, M. Ghiotto, B. Barbarat, D. Olive, The role of Tec protein-tyrosine kinase in T cell signaling, *J. Biol. Chem.* 274 (1999) 607–617.
- [114] M. Sanchez-Lockhart, B. Graf, J. Miller, Signals and sequences that control CD28 localization to the central region of the immunological synapse, *J. Immunol.* 181 (2008) 7639–7648.
- [115] R. Watanabe, Y. Harada, K. Takeda, J. Takahashi, K. Ohnuki, S. Ogawa, et al., Grb2 and Gads exhibit different interactions with CD28 and play distinct roles in CD28-mediated costimulation, *J. Immunol.* 177 (2006) 1085–1091.

- [116] F. Michel, G. Mangino, G. Attal-Bonnefoy, L. Tuosto, A. Alcover, A. Roumier, et al., CD28 utilizes Vav-1 to enhance TCR-proximal signaling and NF-AT activation, *J. Immunol.* 165 (2000) 3820–3829.
- [117] K. Okkenhaug, R. Rottapel, Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction, *J. Biol. Chem.* 273 (1998) 21194–21202.
- [118] M. Nishida, K. Nagata, Y. Hachimori, M. Horiuchi, K. Ogura, V. Mandiyani, et al., Novel recognition mode between Vav and Grb2 SH3 domains, *EMBO J.* 20 (2001) 2995–3007.
- [119] F. Ramos-Morales, B.J. Druker, S. Fischer, Vav binds to several SH2/SH3 containing proteins in activated lymphocytes, *Oncogene* 9 (1994) 1917–1923.
- [120] G.M. Rivera, D. Vasilescu, V. Papayannopoulos, W.A. Lim, B.J. Mayer, A reciprocal interdependence between Nck and PI(4,5)P(2) promotes localized N-WASP-mediated actin polymerization in living cells, *Mol. Cell* 36 (2009) 525–535.
- [121] C.E. Rudd, H. Schneider, Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling, *Nat. Rev. Immunol.* 3 (2003) 544–556.
- [122] C.H. Lin, T. Hunig, Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist, *Eur. J. Immunol.* 33 (2003) 626–638.
- [123] G. Suntharalingam, M.R. Perry, S. Ward, S.J. Brett, A. Castello-Cortes, M.D. Brunner, et al., Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, *N. Engl. J. Med.* 355 (2006) 1018–1028.
- [124] B. Schraven, U. Kalinke, CD28 superagonists: what makes the difference in humans, *Immunity* 28 (2008) 591–595.
- [125] Z. Waibler, L.Y. Sender, C. Merten, R. Hartig, S. Kliche, M. Gunzer, et al., Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies, *PLoS One* 3 (2008) e1708.
- [126] C.H. Chen, D. Piraner, N.M. Gorenstein, R.L. Geahlen, C. Beth Post, Differential recognition of syk-binding sites by each of the two phosphotyrosine-binding pockets of the Vav SH2 domain, *Biopolymers* 99 (2013) 897–907.
- [127] H. Huang, L. Li, C. Wu, D. Schibli, K. Colwill, S. Ma, et al., Defining the specificity space of the human SRC homology 2 domain, *Mol. Cell. Proteomics* 7 (2008) 768–784.
- [128] L.M. O'Rourke, R. Tooze, M. Turner, D.M. Sandoval, R.H. Carter, V.L. Tybulewicz, et al., CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav, *Immunity* 8 (1998) 635–645.
- [129] Z. Songyang, S.E. Shoelson, J. McGlade, P. Olivier, T. Pawson, X.R. Bustelo, et al., *Mol. Cell. Biol.* 14 (1994) 2777–2785.
- [130] L. Tuosto, F. Michel, O. Acuto, p95vav associates with tyrosine-phosphorylated SLP-76 in antigen-stimulated T cells, *J. Exp. Med.* 184 (1996) 1161–1166.

Nicla Porciello received her BSc (Hons) degree (Genetics and Molecular Biology in Basic and Biomedical Research) from Sapienza University of Rome, Italy. In 2013, she started her PhD also at Sapienza University of Rome, which she plans to complete in November 2016. Her current PhD project focuses on the biochemical characterization of the C-terminal proline rich motif of human CD28 in regulating the pro-inflammatory responses of T lymphocytes.



Loretta Tuosto is Associate Professor in Immunology at Sapienza University of Rome and Group Leader of a Research Unit at the Pasteur Institute-Cenci Bolognetti Foundation in Rome, Italy. She received her PhD in Cellular and Molecular Pathology and Biology from Federico II University of Naples, Italy. During her post-doctoral stage at the Pasteur Institute, Paris, France, she developed a well-characterized system to analyze the signal transduction pathways involved in T cell activation and apoptosis. Tuosto's research activity has contributed to the characterization of the molecules involved in CD28-induced activation of NF- κ B signalling pathway in a TCR-independent manner. More recently, Tuosto research's group identified CD28 as a critical regulator of pro-inflammatory functions of specific T cell subsets in Multiple Sclerosis.